Kornimate/medical-research-clean huggingface dataset:
therapeutic effect of transcranial magnetic stimulation on memory impairment in patients after stroke

Conditions: Stroke; Stroke Sequelae; Cognitive Impairment

Summary: the goal of this clinical trial is to test the therapeutic effect of theta burst stimulation (tbs), which is one of stimulus pattern of repetitive transcranial magnetic stimulation, in patients with post stroke cognition impairment (psci). the main questions it aims to answer are: 1. to explore the therapeutic effect of tbs to patients with psci. 2. to compare effect of tbs with different dose. 3. to explore the mechanism of tbs by functional magnetic resonance imaging (fmri). participants will be asked to do: 1. treated with tbs and cognitive training for 3 weeks (15 days). 2. assessed with several scales, including mini-mental state examination (mmse), montreal cognitive assessment (moca), loewenstein occupational therapy cognitive assessment (lotca), wechsler adult intelligence scale-revised in china (wais-rc), wechsler memory scale (wms) before and after treatment. 3. perform the resting fmri, electroencephalogram (eeg) and event related potential before and after treatment. researchers will compare high-dose group, low-dose group and sham group to see if tbs play a role in psci and if the effect of high dose tbs was stronger than low dose.

the procedure of study 1. patients were recruited and agreed with informed consent. 2. all patients were assessed with mmse, moca, lotca, wais and wms, meanwhile they conduct fmri and eeg. target of tbs set at dorsolateral prefrontal cortex (dlpfc). 3. tbs was performed for 15 days (5 days \* 3 weeks). 4. within 3 days after tbs, all patients were assessed with mmse, moca, lotca, wais and wms, meanwhile they conduct fmri and eeg. 5. data acquisition and analysis.

Eligibility criteria:
inclusion criteria: * first-time stroke patients, meeting the diagnostic criteria set by the fourth national conference of cerebrovascular diseases in 1995, and the course of stroke * range from 1 to 12 months; * the vital signs are stable and no progress in neurological signs; * education level: primary school or above, and meeting one of the following conditions: mmse scale ≥ 10 points, and indicating memory decline, with digit span or delayed memory defects. * patients or their family members sign the informed consent form. exclusion criteria: * contraindications or high risks for tbs, such as epilepsy, intracranial metal implants, skull repair; * contraindications for fmri, such as metal implants or claustrophobia; refuse fmri; * drug/alcohol dependence; * cognition or memory dysfunction before the onset; * patients who refuse to cooperate, or can't complete cognitive assessment due to other reasons, such as visual and auditory disturbance, aphasia, agnosia, apraxia.

Keywords: stroke cognitive impairment transcranial magnetic stimulation functional magnetic resonance imaging event related potential
early uvfp management based on neurological evidences (ion-uvfp) - preliminary study

Conditions: Unilateral Vocal Cord Paralysis; Central Auditory Processing Disorder

Summary: the purpose of this preliminary study is to help clarify our hypotheses for the longitudinal study by investigating the relationship between vocal cord paralysis and central auditory processes and thus the interpretation of auditory inputs into the central nervous system.

a very recent study (naunheim et al., 2018) shows that paralysis of a vocal cord can affect central auditory processes, which in turn would have a negative impact on motor control capabilities during voice production. this study was conducted in patients who had undergone type i thyroplasty. to highlight these influences, the authors relied on behavioral tests of auditory perception and vocal production. the investigators would like in this study, based on a similar and existing population at the cliniques universitaires saint-luc, to try to understand the changes observed clinically by proposing to perform vocal production tasks (also planned for the longitudinal study) in the mri. the investigators would like to objectify the differences in the areas involved in the central auditory processes in comparison between patients and control subjects.

Eligibility criteria:
inclusion criteria: * unilateral paralysis in abduction of the vocal cords may be included in the study. * patients who undergone type i thyroplasty (with montgomery implant) at least 3 months ago * control participants without voice disorder exclusion criteria: * wear a pacemaker or other implanted devices (prostheses ...). * wear metal clips, metal in the head, or an adjustable brain drain. * wear non-removable dental appliances (except fillings). * wear cardiac valve prostheses. * have worked the metals. * have a tattoo containing metal particles. * have implanted jewelry (e.g., piercing). * being prone to epileptic seizures. * take medications that alter cortical excitability. * have had a brain surgery. * suffer from intracranial hypertension. * be pregnant or breastfeeding recently. * present allergies that are incompatible with the experimental protocol. * have an abnormal hearing loss in view of their age, identified with tonal and / or vocal audiometry.
pilot study - monitoring the nasal microbiome and viral respiratory infections in newborn hospitalized in neonatalogy.

Conditions: Newborn; Infection

Summary: the objective of our study is therefore to study the evolution of the respiratory microbiome of hospitalized newborns, its interaction with viral infections and their impacts on the evolution of newborns.


Eligibility criteria:
inclusion criteria: * newborn hospitalized in intensive care or neonatal intensive care. * whose parents were able to be informed of the study and who signed consent. * parents affiliate to the social security system exclusion criteria: * refusal of parental consent * parents who are minors or under guardianship, curatorship, safeguard of justice or legal protection. * newborn having already left the hospital/returned home before inclusion * hospitalization beyond the first 48 hours of life * only palliative care.
comparing the efficacy and safety of rezvilutamide+adt+docetaxel versus rezvilutamide +adt in the mhspc

Conditions: Metastatic Prostate Cancer; Hormone Sensitive Prostate Cancer; Chemotherapy Effect

Summary: evaluate whether the combination of rezvilutamide and androgen deprivation therapy (adt) with docetaxel improves overall survival (os) in patients with metastatic hormone-sensitive prostate cancer (mhspc) compared to the combination of rezvilutamide and adt.

to investigate the value of chemotherapy in the treatment of high-burden of mhspc on the background of next-genertion of ar inhibitors.

Eligibility criteria:
inclusion criteria: 1. males aged ≥40 years and ≤80 years. 2. histologically or cytologically confirmed prostate adenocarcinoma. 3. metastatic disease. 4. eligible for adt and docetaxel. 5. started or not started first-generation androgen deprivation therapy (adt), but not exceeding 12 weeks before randomization. 6. ecog score of 0 or 1. 7. laboratory tests meet the following requirements: * hematology: neutrophils ≥1.5×10\^9/l, platelets ≥100×10\^9/l, hemoglobin ≥9g/dl. * renal function: serum creatinine ≤1.5× upper limit of normal (uln). * liver function: aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤2.5× uln, total bilirubin (tbil) ≤1.5× uln. * coagulation function: international normalized ratio (inr) \<1.5. 8. study subjects: patients with mhspc have a confirmed pathology of prostate adenocarcinoma with high tumor burden, which is defined by having at least one of the following conditions: 1) bone scan showing ≥4 bone metastatic lesions (with at least one site outside the pelvis or spine). 2) ct/mri revealing visceral metastatic lesions (excluding lymph nodes). exclusion criteria: patients who meet any of the following criteria are not eligible to participate in this study: 1. prior use of lhrh agonists/antagonists; second-generation androgen receptor (ar) inhibitors such as enzalutamide, arn-509, darolutamide (odm-201), or other investigational ar inhibitors; cyp17 enzyme inhibitors such as abiraterone acetate or oral ketoconazole for anti-tumor treatment of prostate cancer; chemotherapy or immunotherapy for prostate cancer prior to randomization. 2. received radiation therapy/radiopharmaceutical treatment within 2 weeks before randomization. 3. any of the following conditions within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary artery/peripheral artery bypass surgery, congestive heart failure (new york heart association class iii or iv). 4. previous malignancy, except adequately treated basal cell carcinoma or squamous cell carcinoma of the skin or superficial bladder cancer not invading the deeper muscle layer (i.e., ptis, pta, and pt1) and any other cancer in complete remission for at least 5 years before randomization. 5. gastrointestinal diseases or procedures that are expected to significantly interfere with the absorption of study treatment. 6. inability to take oral medication.

Keywords: rezvilutamide mhpsc chemotherapy androgen deprivation therapy
interventions for residual dizziness after successful repositioning maneuvers in patients with bppv

Conditions: Vestibular Disorder

Summary: to investigate the effect of vestibular rehabilitation, with or without medication, on resolving residual dizziness after successful repositioning maneuvers in patients with benign paroxysmal positional.


Eligibility criteria:
inclusion criteria: 1. diagnosed as unilateral bppv (unilateral posterior semicircular canal bppv or horizontal semicircular canal bppv) according to the clinical practice guideline issued by american academy of otolaryngology and head and neck surgery (aao-hnsf) in 2017; 2. aged 18\~80 years; 3. reporting residual symptoms after successful repositioning maneuvers; exclusion criteria: 1. anterior semicircular canal bppv or multicanal bppv; 2. recurrent bppv; 3. subjects with coexisting vestibular disorders, including meniere disease, vestibular neuritis, labyrinthitis, and peripheral vestibular loss; 4. subjects with severe cervical spine disease; 5. subjects with severe cardiovascular diseases ; 6. subjects with known cerebral vascular disease like carotid stenosis; 7. cognitive impairment; 8. suspect of significant depression or anxiety as defined as a score of ≥ 8 for each respective scale of hospital anxiety and depression scale; 9. pregnant/ lactating or planning to become pregnant during the study period; 10. had taken vestibulosupressant, antihistamines, and/ or ototoxic medications in the past 3 months;
patient journey with advanced lung cancer positive for alk fusion in brazil

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: observational, retrospective cohort study that will include patients diagnosed with nsclc and alk rearrangement between january 2015 and december 2020.


Eligibility criteria:
inclusion criteria: * patients older than 18 years; * newly diagnosed advanced stage iiib-iv nsclc (ajcc 8th edition) or locally advance/distant relapse in the period of january 2015 to december 2020. * nsclc with pathological confirmation of alk rearrangement by immunohistochemistry, fluorescent in situ hybridization (fish) or next generation sequencing (ngs); * ecog 0-4; * patients with cns metastases are also considered eligible, regardless of the initial treatment instituted. exclusion criteria: - incomplete medical chart in terms of date of diagnosis, alk test results and outcomes

Keywords: carcinoma non-small-cell lung
pharmacokinetic study in cerebral spinal fluid after a single dose of avi-4020

Conditions: West Nile Virus

Summary: during a clinical study of people with severe west nile virus infections, it was determined that the drug avi-4020 crossed the blood-brain barrier. this study will assess the amount of drug that goes across the blood-brain barrier and the drug levels measured in both the blood and urine. the objective of this study is to find out how much and how fast this drug crosses this barrier.

avi-4020 was designed to interfere with west nile virus translation, and has been shown to cross the blood-brain barrier in both normal and inflamed meninges in a clinical study in patients with severe west nile virus disease. at issue, is whether this observation is limited to avi-4020 pmo drug, or is observed with other pmo drugs. this study is one of three to assess the specific ability of pmo drugs to cross the blood-brain barrier, using similar dosing, and pk assessment time points. in order to rigorously assess the pharmacokinetics, this study is being performed in healthy volunteers at a single point in time. the ability of other pmo drugs to cross the blood-brain barrier will set the stage for future studies that exploit this product characteristic.

Eligibility criteria:
inclusion criteria: * adult males 18 years to 64 years of age; * good general health (as evidenced by no chronic conditions, normal physical exam, vital signs within normal limits; laboratory evaluations within normal range) * signed and dated written informed consent form; and * willing to participate in all study activities and all requirements, including effective contraception (viz., a double-barrier method) during the 7-day study surveillance period. exclusion criteria: * hematology, serum chemistry (exclusive of electrolytes), and urinalysis laboratory test values \>2 times upper limits of normal or anemia (hemoglobulin \<11 g/dl), leukopenia (total white blood count \<3,000/µl or total neutrophils \<1,500/ µl) or thrombocytopenia (platelets \<100,000/µl). electrolytes and coagulation values exceeding normal ranges are to be excluded. * body mass index (bmi) \>35. * calculated creatinine clearance (by the cockroft and gault formula) \<70 ml/min, based on age and gender. * positive hiv-1 or hiv-2 serology. * positive hcv serology and/or positive plasma hcv-rna status. * positive hepatitis b status. * solid or hematopoetic organ transplant recipient. * active illness or recent illness within 30 days of the first dose of study drug. * history of any of the following: brain injury, neoplasm, chronic or migraine headaches, cancer, meningitis or hydrocephalus. * usage of any prescribed, over-the-counter or illicit drug(s) within 30 days of study drug administration. use of herbal remedies and/or supplements at the discretion of the investigator. * unwilling to practice effective contraception during the study period. * participation in any clinical interventional trial within the previous 6 months. * positive drug urine screen.

Keywords: wnv west nile virus wnv meningoencephalitis
intradialytic inspiratory muscle training at different intensities and functional capacity

Conditions: Kidney Failure, Chronic

Summary: investigate the effects of inspiratory muscle training (imt) performed during hemodialysis (hd) procedures in patients with end stage kidney disease (eskd). with intervention of thirty-six imt sessions, performed three times a week, at an intensity of 50%, 30% and 10% (sham) of the maximum inspiratory pressure (mip).

introduction: chronic kidney disease (ckd), especially in its final stage (eskd), is associated with an increased risk of cardiovascular complications and mortality. part of this risk can be attributed to the fact that patients with eskd adopt sedentary behavior. objectives: to investigate the effects of inspiratory muscle training (imt) performed during hemodialysis (hd) procedures in patients with eskd. methodology: randomized double-blind clinical trial, controlled by sham. location: nephrology sector, hospital de clínicas de porto alegre (hcpa) participants: three groups of 12 patients with eskd on hd randomized to three imt intensities. intervention: thirty-six imt sessions, performed three times a week, at an intensity of 50%, 30% and 10% (sham) of the maximum inspiratory pressure (pimax). main outcomes: functional capacity, diaphragm hypertrophy, respiratory muscle strength, lung volume, blood pressure and quality of life. statistical analysis: presentation of data in absolute and relative numbers, and through means and standard deviations. to compare the groups, anova will be used, with significance less than 0.05.

Eligibility criteria:
inclusion criteria: * ckd patients who have been on hd for at least three months; * in physical conditions to perform the tests proposed by the study; * with stable ckd for at least 30 days (with no hospitalization); exclusion criteria: * patients with a recent history of arrhythmias; * recent hospitalization (\<3 months); * recent acute myocardial infarction (\<6 weeks); * hd routine less than 2x / week; * muscle or respiratory changes (eg, chronic obstructive pulmonary disease (copd)); * unstable angina; * severe valve disease; * uncontrolled hypertension; * hemoglobin concentration \<10 g / dl; * participation in a study with intradialytic exercise in the six months preceding this study; * refusal to participate in the study.

Keywords: intradialytic training inspiratory muscle training diaphragm hypertrophy functional capacity end stage kidney disease
magnesium treatment on vitamin d metabolism in participants completed personalized prevention of colorectal cancer trial

Conditions: Colorectal Cancer

Summary: one striking observation is that a large portion of the inter-person variation in serum 25-hydroxyvitamin d (25(oh)d) levels is unexplained. in vitro and in vivo studies indicate vitamin d synthesizing and metabolizing enzymes are mg-dependent. magnesium (mg) supplementation substantially reversed the resistance to vitamin d treatment in patients with magnesium-dependent vitamin-d-resistant rickets. the investigators reported in 2013 from observational studies conducted in the general us population that mg intake significantly interacted with vitamin d intake in affecting vitamin d status as well as interacted with serum 25(oh)d in risk of cardiovascular disease mortality and, maybe, colorectal cancer mortality. the potential interaction between mg and vitamin d was supported by two subsequent studies, including a finnish cohort study and a mouse study. in the parent study (personalized prevention of colorectal cancer trial, nct01105169), the investigators proposed to measure blood concentration of total 25(oh)d as a secondary aim using elisa approach. however, following the novel finding of mg-vitamin d interaction published by the investigators in 2013, they submitted a separate grant application to nci which was funded in 2014. in the new study, the investigators proposed to use a lc-ms approach, which is more accurate and specific than an elisa method, to measure 5 vitamin d metabolites. this new ancillary study allows the investigators to evaluate whether mg supplementation differentially affects vitamin d synthesis and metabolism dependent on baseline serum 25(oh)d levels using existing biospecimens collected in our double-blind placebo-controlled randomized chemoprevention trial.


Eligibility criteria:
inclusion criteria: 1. participants from our parent study (personalized prevention of colorectal cancer trial, nct#01105169, irb#100106); 2. participants who had completed the above study before the time of the sample selection (october 2015); 3. participants consent to store/share samples for future research in colorectal tumors. exclusion criteria: 1. participants cannot provide their blood samples in the parent study.

Keywords: personalized prevention trial magnesium vitamin d metabolism and synthesis magnesium-vitamin d interaction
mulligan stretch with traction versus post isometric relaxtion on hamstring flexibility

Conditions: Hamstring Flexibility

Summary: the design of my study will be randomized control trial (rct) study. and the sampling technique will be non-probability convenience sampling. a sample of 32 (16 in each group) has been selected using 10% level of significance and 80% power of test. three groups will be made each containing 16 participants with inclusion criteria met. group a will be given control group treatment with muscle energy technique applied over the period of 4 weeks. group b will be given control group treatment with mulligan stretch with traction technique applied over the period of 4 weeks. total 3 recordings of hip flexion roms shall be taken with manual goniometry as follows initial/first day, 3rd week, final week/last treatment. a sum of 8 treatments shall be given to the intervention group over the period of 4 weeks, 2 treatments per week.

introduction: mobility in human gait depends on flexibility of hamstring muscles. hamstring muscles function is hip extension and knee flexion. in most of the population, tightness or shortening of hamstring muscles occur which limits hip flexion. to measure hamstring muscles flexibility simple passive slr is performed and range is recorded by manual goniometer. to increase slr, several techniques are used: met's and tslr. effectiveness of these techniques depend on muscle flexibility. objective: the purpose of this study is to compare the effectiveness of mulligan stretch with traction technique and muscle energy technique to increase the slr in athletes with hamstring tightness. method: the data will be collected from athletes in sports clubs, gyms, and sports fields of lahore. the study will be completed in a period of six months after the approval of synopsis. the design of my study will be randomized control trial (rct) study. and the sampling technique will be non-probability convenience sampling. a sample of 32 (16 in each group) has been selected using 10% level of significance and 80% power of test. three groups will be made each containing 16 participants with inclusion criteria met. group a will be given control group treatment with muscle energy technique applied over the period of 4 weeks. group b will be given control group treatment with mulligan stretch with traction technique applied over the period of 4 weeks. total 3 recordings of hip flexion roms shall be taken with manual goniometry as follows initial/first day, 3rd week, final week/last treatment. a sum of 8 treatments shall be given to the intervention group over the period of 4 weeks, 2 treatments per week.

Eligibility criteria:
inclusion criteria: * both male and female * negative spring test * asymptomatic * slr \< 80⸰ exclusion criteria: * positive lbp * lumbar straightening * si joint dysfunction * history of hamstring injury * current musculoskeletal pain in hip region * any other comorbidity limiting joint rom

Keywords: hamstring flexibility sports injury muscle energy technique post isometric relaxation